Related Experiment Video

Updated: Jul 5, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.0K

PARP Inhibitors in Breast Cancer: a Short Communication

Gordon R Daly1,2, Maen Monketh AlRawashdeh3,4, Jason McGrath3

  • 1The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland. gordondaly@rcsi.com.

Current Oncology Reports
|January 18, 2024
PubMed
Abstract

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for treating HER2-negative breast cancer with BRCA mutations. Future research focuses on overcoming resistance and combining PARP inhibitors with other therapies to improve efficacy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a significant therapeutic class in oncology.
  • Approved indications include breast and ovarian cancers, particularly in patients with specific genetic mutations.

Purpose of the Study:

  • To review the current applications of PARP inhibitors in breast cancer treatment.
  • To discuss the limitations and explore future directions for PARP inhibitor therapy.

Main Methods:

  • Review of clinical trial data, including OlympiAD and EMBRACA trials.
  • Analysis of studies on drug mechanisms, efficacy, resistance, and combination therapies.

Main Results:

  • PARP inhibitors are approved for HER2-negative breast cancer with germline BRCA mutations.
  • Key areas of investigation include drug resistance mechanisms and homologous recombination repair (HRR).

Conclusions:

  • Understanding HRR and targeting resistance are crucial for enhancing PARP inhibitor utility.
  • Combining PARP inhibitors with novel agents holds promise for improved clinical outcomes.
Keywords:
BRCABreast cancerHomologous repair deficiencyPARP inhibitor

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K